Quanterix is expanding its biomarker technology platform to oncology with the launch of a new test bed for up to 10-plex assays, which will enable drug developers to expedite clinical trials, says CEO.
TriNetX announced it will add claims data from 190m patients to its network, including ambulatory care, medical claims, and pharmacy claims, to enable researchers to query and analyze the information.
Scientist.com has more than 70 employees across the globe, with offices in San Diego, Boston, the UK – and soon, Japan, with plans to open several satellite offices across the country.
SGS has expanded its Chennai, India-based laboratory with the addition of inductively coupled plasma mass spectrometry systems to address updated ICH Q3D regulatory guidelines.
Charles River is eyeing M&A opportunities in every segment of its business, fueled by global market demand and a “fundamental shift” in the pharmaceutical industry, says CEO.
Yale University is partnering with CROs to provide drug discovery services to awardees of the Blavatnik Fund for Innovation – which aims to bridge the gap between early-stage research and product development.
Marking its sixth acquisition since 2017, BioIVT this week purchased Biological Specialty Corporation (BSC), which expands its ability to offer fresh blood products.
RxCelerate is opening its first office in the US to be closer to clients and meet a "huge demand" for drug discovery and development services in the greater Boston area.
CROs this month have made significant new hires with WCG adding eight to its scientific leadership team, PPD hiring four, and BioIVT filling its new-created role of CCO.
Also, making the move from Bioclinica, David Kiger has been named...
The lawsuit cites more than 150 alleged clinical trial-related deaths since 2014 with plaintiffs calling on the FDA to update current informed consent regulations.
InvVax’s universal flu vaccine candidate has demonstrated preclinical success as the company prepares for a Phase I clinical trial, supported by a Series A fundraising round.
The CRO WuXi AppTec and Schrödinger have launched Faxian Therapeutics, a new company that will focus on accelerating drug discovery and advancing new therapies through global collaboration.
A proof-of-concept study using patient-derived cells to test drug response in clinical trials demonstrates the benefits of precision medicine, movement to which is the future of study design, says researcher.
Velesco Pharma has expanded its analytical research and development capabilities to meet a growing demand for its services after acquiring a new facility in Michigan.
Assay.Works and 2bind are partnering to expand the range of discovery services provided for companies in the pharmaceutical and biotech industry, and academic organizations.
Quotient Sciences, a drug development services organization, will expand its operations with a new early phase formulation development and clinical trial manufacturing facility.
The CRO and software provider for small molecule discovery, Cresset, is collaborating with Elixir to create a new platform for efficient drug discovery.
Evotec AG and Ferring Pharmaceuticals are collaborating to discover and develop new small molecule therapies for the treatment of fertility and gynaecological conditions.
Charles River will manage and provide staffing for NIAID’s vivarium and related research model operations to support biomedical research across multiple scientific disciplines.
Iqvia says its collaboration with Genomics England will help drugmakers and academics draw insights from clinical-genomic datasets – the ‘future of real-world research.’
Researchers are using artificial intelligence to catalyze drug discovery and preclinical drug development - improving predictive models to guide efficient design and optimizing multi-drug regimens, as two recent examples.
Metrion has bolstered its drug discovery leadership team, CluePoints has upped its RBM services, and Concept Life Sciences has added to its analytical services division, among other moves this month in the outsourced pharmaceutical services industry.
Altasciences’ acquisition of a preclinical testing business marks the “next major milestone” in the CRO’s goal to provide an integrated offering from lead candidate selection to proof of concept.
Medicen Paris Region and Cap Digital announced are encouraging their members to support Hu-PreciMED, a precision medicine project launched by Oncodesign, Servier, and Intersystems.
The platform will be designed to help life sciences organizations improve productivity, efficiency, and innovation in early stage drug development, says Accenture executive.
VGXI, a subsidiary of GeneOne, signed a licensing agreement with Houston Methodist Research Institute to produce RNA one of the most valued clinical ingredients.
Evotec and Almirall are using a novel approach to disrupt cell signaling to discover and develop first-in-class therapeutics targeting dermatology diseases.
BioIVT’s research on the mechanisms underlying the C-DILI assay introduces “a new paradigm,” which suggests BSEP inhibition alone will not lead to bile acid-induced liver injury, says study director.
The biopharmaceutical analytical and bioanalytical contract solutions provider SGS is investing more than $1.7m to expand its North American biopharmaceutical testing capabilities.
The Nuvisan Group is taking on part of Galderma’s R&D capacities site, growing its service lines in bioanalysis, clinical trial supplies, and pharmaceutical analytics
This month marked the effective start date for Parexel's new executive VP and CFO Greg Rush, who joins August's People on the Move with several other c-suite hires, including a new CEO at Citoxlab and COO at ProSciento.
IRBM and Merck have signed a new agreement in the peptide therapeutics area through which the Italian CRO will identify potential peptide leads for a specific Merck target.
The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.
